Upcoming event

Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study

Protective effect of LCZ696 on kidney function after partial nephrectomy

Adjuvant therapy after surgical resection of nonmetastatic renal-cell carcinoma: One size does not fit all

Application of the KEYNOTE-564 trial results to real life population: Which patients with advanced kidney cancer should receive adjuvant pembrolizumab

Pembrolizumab outperforms tyrosine kinase inhibitors in the adjuvant therapy of patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis

Decision-making and management strategies for patients with bilateral synchronous non-metastatic renal masses: Insights from a multi-centre European dataset

The detrimental effect of frailty status on renal function recovery after partial nephrectomy – long-term results from a prospective surgical cohort

What happens to the preserved renal parenchyma after clamped partial nephrectomy?

European Urology, May 2022

Prospective evaluation of circulating tumor DNA (ctDNA) in detecting early progression on immune checkpoint inhibitors in patients with advanced genitourinary cancers

Machine learning approach to predict pT3a upstaging of clinically localized renal cell carcinoma and oncological outcomes after surgery (UroCCR 15 study)

Surgical delay after biopsy and risk of upstaging for clinical T1a renal cell carcinoma

Improving decision-making for cytoreductive nephrectomy by evaluating pre-surgical radiographic tumor characteristics

PreviousNext